



IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/723,683
		Filing Date	November 25, 2003
		First Named Inventor	Roth, Richard
		Art Unit	1645
		Examiner Name	To Be Assigned
Total Number of Pages in This Submission	6	Attorney Docket Number	SEQ-4072-UT

### ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____  <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):		
<table border="1"> <tr> <td>Remarks</td> </tr> <tr> <td>SB08 - 1 page cover letter - 2 pages return post card - 1 page transmittal form in duplicate - 2pages</td> </tr> </table>			Remarks	SB08 - 1 page cover letter - 2 pages return post card - 1 page transmittal form in duplicate - 2pages
Remarks				
SB08 - 1 page cover letter - 2 pages return post card - 1 page transmittal form in duplicate - 2pages				

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	BioTechnology Law Group		
Signature			
Printed name	Bruce Grant		
Date	19 SEPT. 2005	Reg. No.	47,608


### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	
Typed or printed name	Bruce Grant
Date	19 SEPT. 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Application No. 10/723,683

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ROTH et al

Examiner: To Be Assigned

Serial No.: 10/723,683

Group Art Unit: 1645

Filed: November 25, 2003

Docket: SEQ-4072-UT

Title: METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND  
TREATMENTS THEREOF

1 P E

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication. Applicants also bring to the Examiner's attention the existance of the following co-pending related applications: (1) application no. 10/723,142 (Attorney Docket: SEQ-4065-UT), November 25, 2003, (2) application no. 10/723,670 (Attorney Docket: SEQ-4067-UT), filed November 25, 2003, (3) application no. 10/723,518 (Attorney Docket: SEQ-4068-UT), filed November 25, 2003, (4) application no. 10/723,681 (Attorney Docket: SEQ-4069-UT), filed November 25, 2003, (5) application no. 10/857,780 (Attorney Docket: SEQ-4069-CP), filed May 27, 2004, and (6) application no. 10/722,939 (Attorney Docket: SEQ-4071-UT), filed November 25, 2003.

**INFORMATION DISCLOSURE STATEMENT**

Serial No.: 10/723,683

Filing Date: November 25, 2003

Title: METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS THEREOF

Page 2


Dkt: SEQ-4072-UT


The listed documents are being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits. Accordingly, it is respectfully submitted no fees are due.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date 19 Sept. 2004  
BioTechnology Law Group  
658 Marsolan Ave.  
Solana Beach, CA 92075  
Telephone: (858) 623-9470  
Fax: (858) 623-9476  
Email: bruce@biotechnologylawgroup.com

By   
Bruce Grant  
Reg. No. 47,608



Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Complete if Known	
		<b>Application Number</b>	10/723,683
		<b>Filing Date</b>	November 25, 2003
		<b>First Named Inventor</b>	Roth, Richard
		<b>Group Art Unit</b>	1645
		<b>Examiner Name</b>	To Be Assigned
Sheet 1 of 1		Attorney Docket No: SEQ-4072-UT	

### US PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	US 5,547,835	Aug-96	Koster	
	A2.	US 5,605,798	Feb-97	Koster	
	A3.	US 5,691,141	Nov-97	Koster	
	A4.	US 5,849,542	Dec-98	Reeve et al.	
	A5.	US 5,869,242	Feb-99	Kamb	
	A6.	US 5,928,906	Jul-99	Koster et al.	
	A7.	US 6,043,031	Mar-00	Koster et al.	
	A8.	US 6,194,144	Feb-01	Koster	
	A9.	US 6,258,538	Jul-01	Koster et al.	
	A10.	US2002/0155440	Oct-02	Ljumbimova et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	A11.	WO 2001/51666	7/19/2001	The General Hospital Corp.		

### OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A12.	Elbashir et al., Methods 26(2):199-213 (2002)	
	A13.	Ezumi et al., Biochem. Biophys. Res. Commun., 277:27-36 (2000)	
	A14.	Forbes, Seminars in Oncology, 24(1)Suppl.1:S1-20 - S1-35 (1997)	
	A15.	Ford et al., British J. Cancer, 72:805-812 (1995)	
	A16.	Miki et al., Science, 266:66-71 (1994)	
	A17.	Wooster et al., Science, 265:2088-2090 (1994)	

EXAMINER

DATE CONSIDERED